ICP-723 (Zurletrectinib) is a potent pan-TRK Inhibitor with IC50 of <1 nM for TRKA, TRKB and TRKC, potently inhibits activities of wild-type and some mutant forms of TRK.
ICP-723 (Zurletrectinib) competitively binds to TRKA/B/C with 100% of inhibition rate at 100 nM.
ICP-723 (Zurletrectinib) demonstrates robust in vitro efficacy in TRK-driven tumor cells, KM12 colorectal cancer cell line bearing TPM3-NTRK1 fusion, as well as a panel of 19 Ba/F3 pro-B murine cell lines over-expressing wild-type.
ICP-723 (Zurletrectinib) also overcomes solvent front mutations (e.g., TRKA G595R, TRKC G623R/E) often developed following 1st generation TRK inhibitor treatment.
ICP-723 (Zurletrectinib) exerts reduced activity in gatekeeper mutations (e.g., TRKA F589L, TRKB F633L, TRKC F617L) and some xDFG mutations (e.g., TRKA G667C/S, TRKB G709C); but retains activity in other xDFG mutations (e.g., TRKA G667A, TRKC G696A/C) and unclassified mutations (e.g., TRKA V573M, TRKA A608D, TRKB V689M).
ICP-723 (Zurletrectinib) (1 mg/kg) causes 89.5% TGI of KM12 tumors in xenograft models.
ICP-723 (Zurletrectinib) (1 or 3 mg/kg) leads to 100% survival of mice bearing Ba/F3 LMNA-NTRK1 G595R tumors, confirms the effectiveness of ICP-723 against solvent front mutant TRKA.